Investigations & Accountability
DOMPÉ AGREES TO PAY $32 MILLION IN MEDICARE KICKBACK SETTLEMENT — Dompé U.S. agreed to pay $32 million to resolve federal False Claims Act allegations involving Medicare co-pays for Oxervate. The pharmaceutical company self-disclosed conduct involving assistance foundations and Oxervate co-pays; the civil resolution does not include a judicial finding of liability.
Gideon follows the money without turning settlement into conviction. Medicare co-pays are designed in part to expose patients and prescribers to price signals. Federal law restricts drug makers from paying remuneration to induce purchases, including indirect payment of a beneficiary’s co-pay obligation. Gideon follows the documentary trail from allegation to resolution.
The government alleged that contributions to two assistance foundations induced Medicare beneficiaries to purchase the drug between 2018 and 2021. That is an attributed position or allegation, not an independently established result. The settled claims remain allegations, and the Justice Department states that there was no determination of liability.
The resolution returns money to the government and rewards self-disclosure and cooperation, but it also warns manufacturers that charitable structures can create kickback exposure when donations and patient-level data influence sales. Patients should not infer that assistance foundations themselves are categorically unlawful.
The record also leaves a defined gap: the company’s internal remediation details beyond the public settlement and how compliance monitoring will operate. Trend surfaces on Google and X were reviewed only as leads. Fox News/Fox Digital, JustTheNews.com, Redacted.inc and OffThePress.com were scanned as required inputs; claims from those outlets were published only when supported by a primary document or independent reporting.
The next checkpoint is concrete: The executed settlement, corporate disclosures and future HHS-OIG enforcement will show the practical aftermath. Until that evidence arrives, the headline must stay narrower than the loudest social-media version. Dompé U.S. agreed to pay $32 million to resolve federal False Claims Act allegations involving Medicare co-pays for Oxervate.
This story belongs to Gideon Marsh on the Investigations & Accountability desk because its institution, evidence and practical consequence match that correspondent’s established coverage role. The named sources below identify the dated action and preserve the line between confirmed facts, allegations and analysis.
For readers affected by the decision, the useful action is to follow the responsible court, agency, election office, company, league or market—not an undated screenshot. The unresolved question remains the company’s internal remediation details beyond the public settlement and how compliance monitoring will operate. FrontPage Crew will update the record when the next verifiable result is published.
Sources
- U.S. Department of Justice — Dompé U.S. Agrees to Pay $32M to Resolve False Claims Act Liability Relating to Self-Disclosure of Patient Kickbacks (09-10-2026)
- HHS Office of Inspector General — Pharmaceutical Manufacturer Assistance Programs guidance (09-10-2026)